Cantor Fitzgerald Forecasts MIRM FY2025 Earnings

Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM) – Stock analysts at Cantor Fitzgerald issued their FY2025 earnings per share estimates for shares of Mirum Pharmaceuticals in a research report issued to clients and investors on Tuesday, January 21st. Cantor Fitzgerald analyst J. Schimmer expects that the company will post earnings of ($1.55) per share for the year. The consensus estimate for Mirum Pharmaceuticals’ current full-year earnings is ($1.45) per share.

Mirum Pharmaceuticals (NASDAQ:MIRM) last issued its quarterly earnings data on Tuesday, November 12th. The company reported ($0.30) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.45) by $0.15. The firm had revenue of $90.38 million during the quarter, compared to the consensus estimate of $81.99 million. Mirum Pharmaceuticals had a negative return on equity of 41.22% and a negative net margin of 31.69%. The business’s revenue for the quarter was up 89.4% compared to the same quarter last year. During the same quarter in the previous year, the company posted ($0.57) EPS.

MIRM has been the subject of a number of other research reports. Citigroup boosted their target price on Mirum Pharmaceuticals from $65.00 to $68.00 and gave the stock a “buy” rating in a research report on Wednesday, November 13th. Leerink Partners lifted their price objective on Mirum Pharmaceuticals from $47.00 to $49.00 and gave the stock an “outperform” rating in a research note on Thursday, October 17th. HC Wainwright reaffirmed a “buy” rating and set a $66.00 price objective on shares of Mirum Pharmaceuticals in a research note on Wednesday, November 13th. Finally, Robert W. Baird boosted their target price on Mirum Pharmaceuticals from $44.00 to $50.00 and gave the company an “outperform” rating in a research note on Wednesday, November 13th. Ten analysts have rated the stock with a buy rating and one has given a strong buy rating to the company’s stock. According to data from MarketBeat.com, the company has a consensus rating of “Buy” and an average target price of $57.10.

Mirum Pharmaceuticals Trading Down 2.6 %

MIRM stock opened at $46.72 on Thursday. The company has a market cap of $2.24 billion, a P/E ratio of -23.13 and a beta of 0.98. Mirum Pharmaceuticals has a twelve month low of $23.14 and a twelve month high of $48.89. The company has a quick ratio of 3.15, a current ratio of 3.34 and a debt-to-equity ratio of 1.33. The business has a fifty day moving average of $43.65 and a 200-day moving average of $41.40.

Insider Buying and Selling

In other Mirum Pharmaceuticals news, SVP Jolanda Howe sold 2,500 shares of the business’s stock in a transaction that occurred on Thursday, November 14th. The stock was sold at an average price of $47.10, for a total transaction of $117,750.00. Following the transaction, the senior vice president now owns 2,426 shares of the company’s stock, valued at $114,264.60. The trade was a 50.75 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, COO Peter Radovich sold 1,998 shares of Mirum Pharmaceuticals stock in a transaction dated Tuesday, January 7th. The stock was sold at an average price of $42.82, for a total transaction of $85,554.36. Following the sale, the chief operating officer now directly owns 27,015 shares of the company’s stock, valued at $1,156,782.30. The trade was a 6.89 % decrease in their position. The disclosure for this sale can be found here. Over the last three months, insiders sold 19,706 shares of company stock worth $875,697. 22.87% of the stock is owned by corporate insiders.

Institutional Investors Weigh In On Mirum Pharmaceuticals

Hedge funds and other institutional investors have recently modified their holdings of the company. Frazier Life Sciences Management L.P. grew its holdings in shares of Mirum Pharmaceuticals by 1.2% during the 3rd quarter. Frazier Life Sciences Management L.P. now owns 6,570,392 shares of the company’s stock worth $256,245,000 after purchasing an additional 75,000 shares in the last quarter. State Street Corp grew its position in Mirum Pharmaceuticals by 19.9% in the third quarter. State Street Corp now owns 1,793,728 shares of the company’s stock valued at $69,955,000 after acquiring an additional 297,511 shares during the last quarter. Geode Capital Management LLC grew its position in Mirum Pharmaceuticals by 3.2% in the third quarter. Geode Capital Management LLC now owns 936,197 shares of the company’s stock valued at $36,519,000 after acquiring an additional 29,017 shares during the last quarter. Lord Abbett & CO. LLC bought a new position in Mirum Pharmaceuticals in the third quarter valued at about $28,913,000. Finally, Clearbridge Investments LLC grew its position in Mirum Pharmaceuticals by 165.5% in the second quarter. Clearbridge Investments LLC now owns 699,933 shares of the company’s stock valued at $23,931,000 after acquiring an additional 436,349 shares during the last quarter.

About Mirum Pharmaceuticals

Mirum Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the development and commercialization of novel therapies for debilitating rare and orphan diseases. Its lead product candidate is LIVMARLI (maralixibat), an orally administered and minimally absorbed ileal bile acid transporter (IBAT) inhibitor that is approved for the treatment of cholestatic pruritus in patients with Alagille syndrome in the United States and internationally.